Cargando…
Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer
Colorectal cancer is one of the top causes of cancer and cancer-related deaths worldwide. The prognosis of metastatic colorectal cancer is poor and treatment options are limited. Many patients will run out of treatment options before they become medically unfit for therapy. As such, there is a need...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667584/ https://www.ncbi.nlm.nih.gov/pubmed/33204182 http://dx.doi.org/10.2147/JEP.S259287 |
_version_ | 1783610342947946496 |
---|---|
author | Cimino, Sarah K Eng, Cathy |
author_facet | Cimino, Sarah K Eng, Cathy |
author_sort | Cimino, Sarah K |
collection | PubMed |
description | Colorectal cancer is one of the top causes of cancer and cancer-related deaths worldwide. The prognosis of metastatic colorectal cancer is poor and treatment options are limited. Many patients will run out of treatment options before they become medically unfit for therapy. As such, there is a need to expand upon the current understanding of disease biology as well as drug resistance mechanisms in order to create new approaches for therapy. In this review article, we will discuss the mechanistic rationale and clinical data for new drugs and therapeutic combinations under development for metastatic colorectal cancer. |
format | Online Article Text |
id | pubmed-7667584 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-76675842020-11-16 Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer Cimino, Sarah K Eng, Cathy J Exp Pharmacol Review Colorectal cancer is one of the top causes of cancer and cancer-related deaths worldwide. The prognosis of metastatic colorectal cancer is poor and treatment options are limited. Many patients will run out of treatment options before they become medically unfit for therapy. As such, there is a need to expand upon the current understanding of disease biology as well as drug resistance mechanisms in order to create new approaches for therapy. In this review article, we will discuss the mechanistic rationale and clinical data for new drugs and therapeutic combinations under development for metastatic colorectal cancer. Dove 2020-11-11 /pmc/articles/PMC7667584/ /pubmed/33204182 http://dx.doi.org/10.2147/JEP.S259287 Text en © 2020 Cimino and Eng. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Cimino, Sarah K Eng, Cathy Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer |
title | Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer |
title_full | Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer |
title_fullStr | Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer |
title_full_unstemmed | Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer |
title_short | Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer |
title_sort | up-and-coming experimental drug options for metastatic colorectal cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667584/ https://www.ncbi.nlm.nih.gov/pubmed/33204182 http://dx.doi.org/10.2147/JEP.S259287 |
work_keys_str_mv | AT ciminosarahk upandcomingexperimentaldrugoptionsformetastaticcolorectalcancer AT engcathy upandcomingexperimentaldrugoptionsformetastaticcolorectalcancer |